Cargando…
FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes
Fibroblast growth factor (FGF) 21, a hormone that increases insulin sensitivity, has shown promise as a therapeutic agent to improve metabolic dysregulation. Here we report that FGF21 directly targets cardiac myocytes by binding β-klotho and FGF receptor (FGFR) 4. In combination with high glucose, F...
Autores principales: | Yanucil, Christopher, Kentrup, Dominik, Li, Xueyi, Grabner, Alexander, Schramm, Karla, Martinez, Eliana C., Li, Jinliang, Campos, Isaac, Czaya, Brian, Heitman, Kylie, Westbrook, David, Wende, Adam R., Sloan, Alexis, Roche, Johanna M., Fornoni, Alessia, Kapiloff, Michael S., Faul, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072546/ https://www.ncbi.nlm.nih.gov/pubmed/35513431 http://dx.doi.org/10.1038/s41598-022-11033-x |
Ejemplares similares
-
Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling
por: Czaya, Brian, et al.
Publicado: (2022) -
FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
por: Grabner, Alexander, et al.
Publicado: (2017) -
CIP4 is required for the hypertrophic growth of neonatal cardiac myocytes
por: Rusconi, Francesca, et al.
Publicado: (2013) -
Correction: CIP4 is required for the hypertrophic growth of neonatal cardiac myocytes
por: Rusconi, Francesca, et al.
Publicado: (2014) -
FGFR4 does not contribute to progression of chronic kidney disease
por: Taylor, Ashlee, et al.
Publicado: (2019)